FOPO – A Late Stage Financing Tool

Inside BIO Industry Analysis

The follow-on public offering (FOPO) market has been strong for biotech since early last year, but has it been open to companies at all stages of drug R&D? It turns out that FOPOs have been utilized primarily by late-stage biotechs.  I recently took a look at FOPOs listed in the Windhover Strategic Transactions database that took place from January 2009 to March 2010. Of the 46 drug development companies that raised over $25M in a follow-on offering, over 88% are late stage (in Phase 3 or product on the market). These 46 represent 95% of the $5.8B raised in the last 15 months.  The chart below shows the total amount raised for each company with red bars for late-stage companies, and black bars for companies in Phase 2 or earlier.

*Companies with two FOPO rounds

Inside BIO Industry Analysis  |  Email This Post  |  Printer Friendly
Tags: ,

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>